RXRX logo

RXRX
Recursion Pharmaceuticals Inc

14,537
Mkt Cap
$1.65B
Volume
14.02M
52W High
$7.18
52W Low
$2.77
PE Ratio
-2.50
RXRX Fundamentals
Price
$3.01
Prev Close
$3.11
Open
$3.10
50D MA
$3.29
Beta
2.69
Avg. Volume
11.02M
EPS (Annual)
-$1.44
P/B
1.56
Rev/Employee
$124,468.33
$1,160.13
Loading...
Loading...
News
all
press releases
Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now
Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now...
News Placeholder
More News
News Placeholder
Recursion Eyes Breakthrough With REC-4881 Drug For Rare Genetic Condition, But Shares Pull Back
Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.read more...
News Placeholder
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
News Placeholder
Recursion Pharmaceuticals Q1 Earnings Call Highlights
Recursion Pharmaceuticals (NASDAQ:RXRX) leadership used its latest earnings call to emphasize a sharper focus on translating artificial intelligence-enabled discovery into clinical and partnership "proof points," while maintaining what it described as tighter financial discipline. CEO and President...
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Quarterly Earnings Results
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 863.37% and a negative return on...
News Placeholder
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +25.42% and -60.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.41, indicating a -1.45% shift from the previous trading day.
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $10.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. cut their price objective on Recursion Pharmaceuticals from $11.00 to $10.00 and set an "overweight" rating for the company in a report on Thursday...
News Placeholder
LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised
LLY jumps after crushing Q1 estimates and raising 2026 outlook, powered by surging Mounjaro and Zepbound sales and strong global demand.
News Placeholder
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know
Recursion Pharmaceuticals (RXRX) closed at $3.3 in the latest trading session, marking a -3.23% move from the prior day.
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available